Lori J Goldstein

Lori J Goldstein

UNVERIFIED PROFILE

Are you Lori J Goldstein?   Register this Author

Register author
Lori J Goldstein

Lori J Goldstein

Publications by authors named "Lori J Goldstein"

Are you Lori J Goldstein?   Register this Author

70Publications

1786Reads

30Profile Views

Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.

Clin Breast Cancer 2019 Apr 20;19(2):97-104.e4. Epub 2018 Dec 20.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.011DOI Listing
April 2019

Treatment delays from transfers of care and their impact on breast cancer quality measures.

Breast Cancer Res Treat 2019 Feb 15;173(3):603-617. Epub 2018 Nov 15.

Data Working Group, The National Accreditation Program for Breast Centers, American College of Surgeons, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-5046-x
Publisher Site
http://dx.doi.org/10.1007/s10549-018-5046-xDOI Listing
February 2019

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

J Clin Oncol 2018 09 24;36(25):2621-2629. Epub 2018 Jul 24.

Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Anne O'Neill, Dana-Farber Cancer Institute, Boston, MA; William Gradishar, Northwestern University, Chicago; Nguyet Anh Le-Lindqwister, Heartland Cancer Research National Cancer Institute Community Oncology Research Program, Peoria, IL; Timothy J. Hobday, Mayo Clinic, Rochester; Stuart Bloom, Abbott Northwestern Hospital, Minneapolis, MN; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia; Adam M. Brufsky, University of Pittsburgh, Pittsburgh, PA; Ingrid A. Mayer, Vanderbilt University, Nashville, TN; Amye J. Tevaarwerk, University of Wisconsin, Madison, WI; Joseph A. Sparano, Montefiore Hospital and Medical Center, Bronx; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Carolyn B. Hendricks, Association Community Clinical Oncology Program, Bethesda, MD; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; and George W. Sledge JR, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118403PMC
September 2018

Profile of abemaciclib and its potential in the treatment of breast cancer.

Onco Targets Ther 2018 29;11:5253-5259. Epub 2018 Aug 29.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S149245DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120573PMC
August 2018

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

J Clin Oncol 2018 06 17;36(16):1556-1563. Epub 2018 Apr 17.

Noah Kornblum, Della F. Makower, and Joseph A. Sparano, Albert Einstein College of Medicine, Bronx; Paula Klein, Mount Sinai Beth Israel Comprehensive Cancer Center, New York, NY; Fengmin Zhao and Judith Manola, Dana-Farber Cancer Institute, Boston, MA; Bhuvaneswari Ramaswamy, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Adam Brufsky, University of Pittsburgh, Pittsburgh; Cristina I. Truica, Penn State Cancer Institute, Hershey; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Phillip J. Stella, Saint Joseph Mercy (Michigan Cancer Consortium), Ann Arbor, MI; Brian Burnette, Saint Vincent Hospital, Green Bay; Timothy R. Wassenaar, Pro Health Care, Waukesha, WI; Melinda Telli, Stanford University School of Medicine, Stanford, CA; Puneet Cheema, Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, MN; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Gamini S. Soori, Missouri Valley Cancer Consortium, Omaha, NE; Barbara Haley, UT Southwestern Medical Center, Dallas, TX; and Kathy D. Miller, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.9331DOI Listing
June 2018

Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.

Breast Cancer Res Treat 2016 12;160(3):573

Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C-308, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4023-5DOI Listing
December 2016

Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.

Breast Cancer Res Treat 2016 11 17;160(1):153-162. Epub 2016 Sep 17.

Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C-308, Philadelphia, PA, 19111, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064835PMC
http://dx.doi.org/10.1007/s10549-016-3982-xDOI Listing
November 2016

NCCN Guidelines Insights Breast Cancer, Version 1.2016.

J Natl Compr Canc Netw 2015 Dec;13(12):1475-85

From Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Washington/Seattle Cancer Care Alliance; UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Colorado Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Mayo Clinic Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Duke Cancer Institute; Vanderbilt-Ingram Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; Roswell Park Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Research Advocacy Network; Moffitt Cancer Center; City of Hope Comprehensive Cancer Center; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0176DOI Listing
December 2015

Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.

J Natl Compr Canc Netw 2015 Aug;13(8):947-52

From Fox Chase Cancer Center, Temple University Heath System, Philadelphia; Abington Memorial Hospital, Abington; and Molecular Therapeutics Research Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. From Fox Chase Cancer Center, Temple University Heath System, Philadelphia; Abington Memorial Hospital, Abington; and Molecular Therapeutics Research Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763101PMC
http://dx.doi.org/10.6004/jnccn.2015.0115DOI Listing
August 2015

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

J Clin Oncol 2015 Jun 6;33(17):1895-901. Epub 2015 Apr 6.

Melinda L. Telli, Kristin C. Jensen, Shaveta Vinayak, Allison W. Kurian, Jafi A. Lipson, Patrick J. Flaherty, Elizabeth A. Schackmann, Irene L. Wapnir, Robert W. Carlson, Pei-Jen Chang, and James M. Ford, Stanford University School of Medicine, Stanford; Bobbie Head, Marin Specialty Care, Greenbrae, CA; Kirsten Timms, Victor Abkevich, Julia E. Reid, and Anne-Renee Hartman, Myriad Genetics, Salt Lake City, UT; Joseph A. Sparano, Albert Einstein College of Medicine, New York, NY; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Barbara Haley, University of Texas Southwestern Medical Center, Dallas, TX; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; and Judith Manola, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451172PMC
June 2015

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N Engl J Med 2015 Mar;372(10):923-32

From the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); SWOG Cancer Research Group Statistical Center, Fred Hutchinson Cancer Research Center (J.M.U., W.E.B.), and Seattle Cancer Care Alliance and University of Washington (J.G.) - all in Seattle; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (K.-A.P., P.A.F.), Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) (K.-A.P., P.A.F., J.F.F.), Calvary Mater Hospital, Newcastle, NSW (F.B., J.M.L., J.F.F.), and University of Sydney, Sydney (F.B.) - all in Australia; International Breast Cancer Study Group (IBCSG), Bern, Switzerland (K.-A.P., P.A.F.); National Institute of Oncology, Budapest, Hungary (E.H.); Auckland Regional Cancer and Blood Service, Auckland, New Zealand (D.P.); Fox Chase Cancer Center, Philadelphia (L.J.G.); Instituto de Enfermedades Neoplasicas (H.L.G.) and Oncosalud SAC (C.S.V.), Lima, Peru; Dana-Farber Cancer Institute (A.H.P., R.D.G.) and IBCSG Statistical Center (R.D.G.) - both in Boston; Wichita Community Clinical Oncology Program, Wichita (S.R.D.), and University of Kansas, Westwood (C.J.F.) - both in Kansas; University of Southern California Norris Cancer Center, Los Angeles (A.A.G.), the Angeles Clinic and Research Institute, Santa Monica (S.M.), and University of California at Irvine Chao Family Comprehensive Cancer Center, Orange (F.L.M) - all in California; National Cancer Institute, Division of Cancer Prevention, Bethesda, MD (L.M.); M.D. Anderson Cancer Center, Houston (G.N.H.); and Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL (K.S.A.).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/obgynsurvey/2015/06000/Gosereli
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1413204
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1413204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231PMC
March 2015

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

J Clin Oncol 2015 Feb 22;33(4):340-8. Epub 2014 Dec 22.

Antonio C. Wolff, Amanda L. Blackford, Kala Visvanathan, Terry S. Langbaum, and Judith E. Karp, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Hope S. Rugo, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Beverly Moy, Massachusetts General Hospital Cancer Center; Melissa E. Hughes and Jane C. Weeks, Dana-Farber Cancer Institute, Boston, MA; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Keith Stockerl-Goldstein, Siteman Cancer Center at Washington University School of Medicine, St Louis, MO; Leigh Neumayer, Huntsman Cancer Center at University of Utah School of Medicine, Salt Lake City, UT; and Richard L. Theriault, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.6119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302215PMC
February 2015

Skin involvement and breast cancer: are T4b lesions of all sizes created equal?

J Am Coll Surg 2014 Sep 20;219(3):534-44. Epub 2014 Apr 20.

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamcollsurg.2014.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143438PMC
September 2014

How do I follow patients with early breast cancer after completing adjuvant therapy.

Curr Treat Options Oncol 2014 Mar;15(1):63-78

Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-013-0265-1DOI Listing
March 2014

Reducing the time from initial call to first appointment: the impact of patient access redesign and a nurse navigation program.

J Natl Compr Canc Netw 2014 Feb;12 Suppl 1:S16-8

From the aBreast Evaluation Center, bQuality Management, cWomen's Cancer Center, and dNCCN Breast Outcomes Project, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0207DOI Listing
February 2014

TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.

Breast Cancer Res Treat 2012 Jul 16;134(2):751-7. Epub 2012 Jun 16.

Weiler Division, Montefiore-Einstein Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, 1825 Eastchester Rd., Bronx, NY 10461, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2112-7
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2112-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965271PMC
July 2012

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.

Clin Cancer Res 2011 Nov 25;17(21):6905-13. Epub 2011 Oct 25.

Department of Medicine, Division of Hematology, Oncology, Geffen School of Medicine, UCLA Medical Center, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0288DOI Listing
November 2011

History of smoking is associated with younger age at diagnosis of breast cancer.

Breast J 2010 Jul-Aug;16(4):344-9. Epub 2010 Apr 21.

Department of Radiation Oncology, University of Miami, Miller School of Medicine, Miami, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4741.2010.00921.xDOI Listing
November 2010

Optimizing chemotherapy regimens for patients with early-stage breast cancer.

Clin Breast Cancer 2010 ;10 Suppl 1:E8-15

Fox Chase Cancer Center, Philadelphia, PA 19111-2412, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15268209117009
Publisher Site
http://dx.doi.org/10.3816/CBC.2010.s.002DOI Listing
October 2010

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.

Clin Cancer Res 2009 Dec;15(24):7693-7700

Authors' Affiliations: Eastern Cooperative Oncology Group, Brookline, Massachusetts; Sanofi-Aventis, Bridgewater, New Jersey; Genomic Health, Inc., Redwood City, California; North Central Cancer Treatment Group, Rochester, Minnesota; Cancer and Leukemia Group B, Chicago, Illinois; and Southwest Oncology Group, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-09-1450DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396025PMC
December 2009

Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.

Authors:
Lori J Goldstein

Breast Care (Basel) 2008;3(s2):25-28. Epub 2008 Oct 16.

Fox Chase Cancer Center, Philadelphia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000151733DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930999PMC
October 2008

Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.

J Natl Compr Canc Netw 2007 Oct;5(9):875-82

Fox Chase Cancer Center Partners, Division of Extramural Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19046, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2007.0078DOI Listing
October 2007

Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.

Int J Radiat Oncol Biol Phys 2007 Jun 26;68(2):347-53. Epub 2007 Mar 26.

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2006.12.035DOI Listing
June 2007

Controversies in adjuvant endocrine treatment of premenopausal women.

Authors:
Lori J Goldstein

Clin Breast Cancer 2006 Feb;6 Suppl 2:S36-40

Breast Evaluation Center, Fox Chase Cancer Center, Philadelphia, PA 19111-2412, USA.

View Article

Download full-text PDF

Source
February 2006

American Society for Clinical Oncology 40th annual meeting, New Orleans, LA, 5-8 June 2004: breast cancer highlights.

Breast Cancer Res 2004 6;6(6):275-8. Epub 2004 Oct 6.

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr944DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064087PMC
April 2005

Prognostic and predictive factors in early-stage breast cancer.

Oncologist 2004 ;9(6):606-16

D.O., Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, Pennsylvania 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.9-6-606DOI Listing
March 2005

Taxanes in the adjuvant treatment of breast cancer.

J Natl Compr Canc Netw 2003 Apr;1(2):222-31

Breast Evaluation Center, Philadelphia, Pennsylvania 19111-2412, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2003.0021DOI Listing
April 2003